Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart TagsBone & JointCardiovascularCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
The 8 Case Studies from Antinol® Case Study Contest of 2020.
1st Winning Awards
1) Use of PCSO-524® and Cyclosporin for Treatment of Immune-Mediated Polyarthritis in Dogs
2) Use of PCSO-524® for Supplementary Treatment of Protein Losing Nephropathy in Animals
2nd Winning Awards
3) Use of PCSO-524®(Antinol®) in a Pomeranian Dog with Degenerative Mitral Valve Disease (DMVD) and Cardiac Tumor of the Left Atrium
3rd Winning Awards
4) Use of PCSO-524 (Antinol®) for Treatment of Chronic Pododermatitis in FIghting Cocks
5) Use of PCSO-524® with Physical Rehabilitation to Regain Mobility in Dogs after Femoral Head and Neck Excision
6) Use of PSCO-524® (Antinol®) and Casting for Treatment of Tetraparesis and Neck Pain Due to Atlantoaxial Instability and Subluxation of the 1st-2nd Cervical Vertebrae
7) Effect of One Year Treatment with PCSO-524® on Feline Dermatophytic Pseudomycetoma
An intact male Shih Tzu dog weighed 5.8 kilograms was referred to Suvarnachad Animal Hospital with signs of polydipsia, polyuria, edema and ascites due to accumulation of fluid in the abdominal cavity.
Biochemical tests found hypoalbuminemia, hyperglobulinemia, hypercholesterolemia, increased urine protein creatinine ratio (UPC) to 5.88 and no signs of inflammation or infection of the urinary tract.
Protein losing nephropathy from glomerular disease was diagnosed based on the biochemical indicators. Medication was given to the dog in order to control kidney damage and minimize the clinical symptoms.
Anti-proteinuric drug, for example ACE inhibitor to reduce blood pressure, was particularly selected for the treatment in conjunction with prednisolone and PCSO-524® as supplementary treatment.
During the 10 months follow up, the dog showed improvement of clinical symptoms, no edema, lack of accumulation of fluid in abdomen cavity, and serum albumin that was increased to normal level.
Use of PCSO-524® Along with Physical Therapy for Controlling Pain and Inflammation in a Cat Suffering from Osteoarthritis, Chronic Kidney Disease and Triaditis
A spayed female domestic shorthaired cat aged 21 years and weighed 4.2 kilograms with history of chronic kidney disease and triaditis was referred to Suvarnachad Animal Hospital.
The cat showed signs of both hind limb weakness, limp tail and pain around posterior body part. Other signs included polydipsia, polyuria, and diarrhea. Radiographic examination revealed osteoarthritis at lumbosacral joint, elbow and both stifle joints. Hematological and blood chemistry tests showed mild anemia, neutrophilic leukocytosis, increased serum amyloid A and Increased Feline pancreatic lipase.
Administration of PCSO-524® and physical therapy were provided to reduce systematic and local pain and inflammation. The supportive treatment was continued for 15 months, during the first 2 months of which, the lumbosacral joint painwas reduced and then disappeared after 5 months. The control of elbow and knee joint pain was satisfied for the whole treatment period.
The cat was able to move the tail and resume normal walking after the 1st and 5th month of the treatment, respectively. Ability to jump and climb returned in the 5th and 8th month. However, the cat had improved defecation within 3 months. Testing of feline pancreatic lipase and serum amyloid A showed normal levels after 7 months of the treatment.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted